Yuankai Shi

Yanqiu Zhao, Y. Shu, Gong-yan Chen, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

H Zhao, Peng Wu, W. Zhong, 2023, BMC Cancer.

Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC

Lin Li, T. Xie, Yuankai Shi, 2023, Cancer Immunology, Immunotherapy.

Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization

Haolong Li, Yuankai Shi, C. Zheng, 2023, Journal of Hematology & Oncology.

Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)

Chuan Jin, Zhi-gang Peng, Xiao-hong Zhang, 2023, Cancer Immunology, Immunotherapy.

Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients

P. Liu, Jian-liang Yang, Sheng Yang, 2023, European journal of haematology.

Subgroup analysis in patients (pts) with non-squamous (N-Sq), EGFR-wild type (wt), second/third-line NSCLC from the global phase (Ph) 3 trial DUBLIN-3 (BPI-2358-103) with the plinabulin/docetaxel (Plin/Doc) combination versus Doc alone.

M. Chen, R. Mohanlal, Yan Sun, 2022, Journal of Clinical Oncology.

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

B. Han, K. Li, P. Yu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma

Xiaobo Yu, Guibin Wang, Q. Zhong, 2023, Molecular & cellular proteomics : MCP.

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges

H. Yao, Ying Cheng, Bing-he Xu, 2020, Cancer biology & medicine.

Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

Ying Cheng, Yue-Yin Pan, Yong He, 2023, Journal of Cancer Research and Clinical Oncology.

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

F. Cavalli, M. Ogura, M. Hino, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

吉非替尼治疗EGFR基因突变状态不明的青年晚期肺腺癌疗效分析

Junling Li, X. Hao, Ziping Wang, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer

Xingsheng Hu, Fang Lv, Yuankai Shi, 2023, Frontiers in Immunology.

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis

Xingsheng Hu, Yu Feng, Y. Tao, 2023, Thoracic cancer.

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study

C. Bai, Yi-long Wu, G. Jiang, 2013, Clinical and Translational Oncology.

Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study

Jian-liang Yang, Shengyu Zhou, Q. Zhong, 2023, Annals of hematology.

Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.

Fei Liu, Ying Cheng, Jian Feng, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination

Yuankai Shi, C. Zheng, Zhishang Zhang, 2023, Expert review of vaccines.

High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer

Liling Huang, Yuankai Shi, C. Zheng, 2024, Molecular & cellular proteomics : MCP.

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study

J. Ying, P. Cao, Y. Bai, 2024, EBioMedicine.

Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing

Liling Huang, T. Xie, Yuankai Shi, 2023, Cancer Immunology, Immunotherapy.

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer

J. Cui, Lejie Cao, Yuankai Shi, 2024, The Lancet regional health. Western Pacific.

Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer

Yuankai Shi, Ruyun Gao, Xiaohong Han, 2024, Journal of translational medicine.

Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study

Chuan Jin, T. Sun, Yuankai Shi, 2024, BMC cancer.

Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma

Liling Huang, Yuankai Shi, Sheng Yang, 2024, Cancer immunology, immunotherapy : CII.